Case Update: In May 2022, In Vitro Sciences, and its parent company, Women’s Health USA, agreed to pay a $2.85 million settlement to resolve claims they artificially raised the price of in vitro fertilization (IVF) services. More information about the settlement can be found here.

FeganScott joined in the filing of an antitrust class action lawsuit on behalf of victims of an alleged anticompetitive scheme spearheaded by physician practice management company, In Vitro Sciences, and its parent company, Women’s Health USA.

According to the suit, In Vitro Sciences used contracts with the Center for Advanced Reproductive Services (CARS) and Reproductive Medicine Associates of Connecticut (RMACT) to drive revenue as high as possible for its assisted reproductive technology (ART) services such as egg freezing and in vitro fertilization (IVF). Furthermore, the lawsuit states that In Vitro Sciences jointly negotiated reimbursement rates that CARS and RMACT received from health insurance companies for their assisted reproductive technology services, ultimately fixing the prices and terms and conditions for ART services provided in Connecticut.

The class action lawsuit seeks to recover damages incurred by the class represented, all of whom paid higher prices for ART services in Connecticut than they would have paid in a competitive market, as a result of the alleged anticompetitive scheme.